Eli Lilly and Company (LLY) announced on Tuesday that its drug Kisunla has received approval from Japan's Ministry of Health, Labour and Welfare for treating adults with early symptomatic Alzheimer's disease.
The approval stems from the promising results of the TRAILBLAZER-ALZ 2 Phase 3 study, which demonstrated that Kisunla significantly decelerates the decline in memory, cognitive abilities, and daily functioning in patients with early symptomatic Alzheimer's.
Japan becomes the second major market to approve Kisunla, following its earlier approval in the United States this past July.
